Acesso livre
Acesso livre

Endocrinologia

Análise de especialista | Dose ideal de aspirina para a prevenção secundária em pacientes com doença cardiovascular aterosclerótica (DCVA) – “Uma estratégia de aspirina em baixa dose é melhor para a maioria dos pacientes com DCVA dada a efetividade similar, menor risco de sangramento e melhor adesão geral.”

26 Ago, 2021 | 12:17h

Ideal Aspirin Dose for Secondary Prevention in Patients With ASCVD – American College of Cardiology

Conteúdo relacionado: #ACC21 – RCT: No significant differences in cardiovascular events or major bleeding between patients receiving 81 mg vs. 325 mg of aspirin daily.

Nova diretriz USPSTF recomenda que indivíduos com sobrepeso e obesidade sejam submetidos a rastreamento para pré-diabetes e diabetes tipo 2 a partir dos 35 anos de idade, e não mais a partir dos 40 anos.

25 Ago, 2021 | 13:12h

Final Recommendation Statement: Screening for Prediabetes and Type 2 Diabetes – U.S. Preventive Services Task Force

Editoriais:

New USPSTF Recommendations for Screening for Prediabetes and Type 2 Diabetes: An Opportunity to Create National Momentum – JAMA

Updated USPSTF Screening Recommendations for Diabetes: Identification of Abnormal Glucose Metabolism in Younger Adults – JAMA Internal Medicine

Entrevista com a autora: USPSTF Recommendation: Screening for Prediabetes and Type 2 Diabetes – JAMA

Relatório de evidência: Screening for Prediabetes and Type 2 Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

Página do paciente JAMA: Screening for Prediabetes and Type 2 Diabetes

Estudo randomizado | Ablação suprarrenal baseada em cateter reduz o aldosteronismo primário.

25 Ago, 2021 | 13:07h

Catheter-Based Adrenal Ablation Remits Primary Aldosteronism: A Randomized Medication-Controlled Trial – Circulation (gratuito por tempo limitado)

 

Comentário no Twitter

 

Coisas que fazemos sem motivo nenhum: suspensão rotineira de metformina no hospital.

25 Ago, 2021 | 13:00h

Things We Do For No Reason™: Routinely Holding Metformin in the Hospital – Journal of Hospital Medicine

Estudo randomizado | Suplementação de vitamina D não tem efeito sobre a função renal de adultos pré-diabéticos.

25 Ago, 2021 | 12:58h

Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial – Clinical Journal of the American Society of Nephrology (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 

Estudo randomizado | Inibidores de SGLT2 reduzem o risco de hiperpotassemia em pacientes com diabetes e doença renal crônica.

24 Ago, 2021 | 11:36h

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial – European Heart Journal (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 

Diretriz ACOG | Prevenção, rastreamento e diagnóstico de osteoporose.

23 Ago, 2021 | 13:05h

Osteoporosis Prevention, Screening, and Diagnosis: ACOG Clinical Practice Guideline No. 1 – Obstetrics & Gynecology

M-A | Agonistas receptores de GLP-1 reduzem eventos cardiovasculares adversos maiores, mortalidade por todas as causas, admissão hospitalar por insuficiência cardíaca e piora na função renal em pacientes com diabetes tipo 2.

23 Ago, 2021 | 12:58h

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)

Conteúdo relacionado: Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.

M-A | O papel dos inibidores de SGLT2 na insuficiência cardíaca.

23 Ago, 2021 | 12:56h

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis – Cardiology Research and Practice

Conteúdos relacionados:

ESC Position Paper: Cardiac, renal, and metabolic effects of SGLT2 inhibitors.

Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.

Summary: SGLT2 inhibitors and GLP-1 receptor agonists established and emerging indications.

M-A: SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure.

Meta-analysis: Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with Type 2 diabetes

#ESCCongress – [Abstract Only] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

[Abstract Only] Randomized Trial: SGLT2 Inhibitor Improves Outcomes in Patients with Heart Failure Even in the Absence of Diabetes

Estudo de coorte | Desfechos cardiovasculares e renais dentro do espectro glicêmico – Pré-diabetes e diabetes tipo 2 foram independentemente associados a doença cardiovascular aterosclerótica.

18 Ago, 2021 | 12:35h

Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank – Journal of the American College of Cardiology

Comentário: Cardiovascular and Kidney Outcomes in Diabetes and Prediabetes – American College of Cardiology

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.